Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation

Table 2 Cox regression analysis of recurrence after radiofrequency in patients with hepatocellular carcinoma

Characteristics	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Gender
Male	1
Female	1.52	0.83-2.80	0.174
Age (years)	1.01	0.99-1.04	0.300
BMI (kg/m2)	1.08	0.32-3.71	0.898
WBC (× 109/L)	0.93	0.82-1.06	0.284
HGB (g/L)	1.00	0.99-1.01	0.972
PLT (× 109/L)	1.01	0.99-1.20	0.853
INR	1.07	0.35-3.31	0.906
ALB (g/L)	1.00	0.96-1.04	0.895
AST (U/L)	0.99	0.98, 1.00	0.167
ALP (U/L)	1.00	0.99-1.01	0.736
TBIL (μmol/L)	0.99	0.97-1.01	0.292
eGFR (mL/min/1.73 m2)	0.98	0.95-1.06	0.312
HBsAg (lgIU/mL)	1.03	0.78-1.36	0.855
HBeAg
NEG	1
POS	1.29	0.75-2.21	0.363
HBV DNA
NEG	1
POS	0.86	0.48-1.55	0.626
Child-Pugh
A	1
B	3.88	0.45-33.21	0.216
ALT (U/L)	0.99	0.97-1.00	0.074	0.99	0.97-1.01	0.097
GGT (U/L)	1.00	1.00-1.01	0.004	1.01	1.00-1.01	0.026
AFP (ng/mL)	0.88	1.00-1.02	0.074	1.01	1.00-1.01	0.013
Anti-HBV therapy
ETV	1			1
TDF	0.57	0.35-0.90	0.017	0.62	0.38-1.02	0.047
TAF	0.52	0.30-0.91	0.021	0.57	0.32-1.02	0.046
BCLC
0	1			1
A	3.70	1.36-10.05	0.010	3.82	1.39-10.47	0.009

ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide fumarate; BMI: Body mass index; WBC: White blood cell; ALB: Albumin; ALT: Alanine aminotransferase; HGB: Hemoglobin; PLT: Platelet; TBIL: Total bilirubin; eGFR: Estimated glomerular filtration rate; INR: International normalized ratio; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; GGT: γ-glutamyl transpeptidase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; NEG: Negative; POS: Positive; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer.